Key result
Eptifibatide significantly reduced the 30-day composite of death or myocardial infarction compared to placebo (14.2% vs. 15.7%; p = 0.042) in patients with non-ST-segment elevation ACS.
Why the study?
Does eptifibatide reduce the composite of death or myocardial infarction in patients with non-ST-segment elevation acute coronary syndromes?
Population
Almost 11,000 patients with non-ST-segment elevation acute coronary syndromes (ACS)
Comparison
Eptifibatide (glycoprotein IIb-IIIa inhibitor) vs Placebo
Design
Review
Follow-up
30 days
Authors
Loading...
Eptifibatide approval for non-ST-elevation ACS rests on trial data; leaves open its role versus contemporary therapies.
RCT (n=11,000)
Does eptifibatide reduce the composite of death or myocardial infarction in patients with non-ST-segment elevation acute coronary syndromes?
Absolute Event Rate: 14.2% vs 15.7%
p-value: p=0.042
Eptifibatide significantly reduces the composite of death or myocardial infarction at 30 days in patients with non-ST-segment elevation ACS, regardless of whether an invasive or conservative management strategy is pursued.
Fintel et al. (2000) conducted an RCT in non-ST-segment elevation acute coronary syndromes (ACS) (n=11,000). Eptifibatide vs. Placebo was evaluated on Composite of death or myocardial infarction at 30 days (p=0.042). Eptifibatide significantly reduced the 30-day composite of death or myocardial infarction compared to placebo (14.2% vs. 15.7%; p = 0.042) in patients with non-ST-segment elevation ACS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: